This PTP1B ASO led to a second-generation ASO known as IONIS-PTP-1BRx that is currently in Phase II clinical trials for the treatment of type 2 diabetes in overweight patients (112). The gene discussed is PTPN1; the disease is type 2 diabetes mellitus.